Literature DB >> 25806174

TRAIL apoptotic pathway-targeted therapies for NSCLC.

Anita C Bellail1, Chunhai Hao1.   

Abstract

Entities:  

Year:  2012        PMID： 25806174      PMCID： PMC4367575          DOI： 10.3978/j.issn.2218-6751.2012.02.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  24 in total

1.  Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

Authors:  Jean-Charles Soria; Zsuzsanna Márk; Petr Zatloukal; Barna Szima; István Albert; Erzsébet Juhász; Jean-Louis Pujol; Jerzy Kozielski; Nigel Baker; Dominic Smethurst; Yong-jiang Hei; Avi Ashkenazi; Howard Stern; Lukas Amler; Yang Pan; Fiona Blackhall
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

2.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

3.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

4.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

Review 5.  Gefitinib--a novel targeted approach to treating cancer.

Authors:  Roy S Herbst; Masahiro Fukuoka; José Baselga
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

6.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Authors:  Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Jänne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

7.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245

8.  Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Authors:  Ruth Plummer; Gerhardt Attard; Simon Pacey; Louise Li; Albiruni Razak; Rebecca Perrett; Mary Barrett; Ian Judson; Stan Kaye; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Hilary Calvert; Johann de Bono
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

9.  Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.

Authors:  Jin H Song; Margaret C L Tse; Anita Bellail; Surasak Phuphanich; Fadlo Khuri; Norman M Kneteman; Chunhai Hao
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

10.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Authors:  Anthony W Tolcher; Monica Mita; Neal J Meropol; Margaret von Mehren; Amita Patnaik; Kristin Padavic; Monique Hill; Theresa Mays; Therese McCoy; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Roger B Cohen
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544
View more
  1 in total

1.  Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.

Authors:  Alfiah Noor; Ijeoma Adaku Umelo; Peter Kronenberger; Philippe Giron; Elly De Vlieghere; Olivier De Wever; Erik Teugels; Jacques De Grève
Journal:  Oncotarget       Date:  2018-06-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.